The Carlyle Group made a strategic growth investment and will acquire a majority stake in TriNetX, a global health research network focused on clinical research to bring new therapies to market faster.
Terms of the deal were undisclosed.
The $221 billion private equity giant has invested more than $15 billion of equity since inception in healthcare-oriented companies.
“With a deep clinical focus and a highly scalable data strategy, we believe TriNetX is well positioned for continued organic and inorganic growth opportunities,” said Joe Bress, a principal specializing in healthcare at The Carlyle . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.